EA201590890A1 - Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу - Google Patents
Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группуInfo
- Publication number
- EA201590890A1 EA201590890A1 EA201590890A EA201590890A EA201590890A1 EA 201590890 A1 EA201590890 A1 EA 201590890A1 EA 201590890 A EA201590890 A EA 201590890A EA 201590890 A EA201590890 A EA 201590890A EA 201590890 A1 EA201590890 A1 EA 201590890A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyridin
- fluor
- derivatives
- amine containing
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относится к производным 5-фтор-N-(пиридин-2-ил)пиридин-2-амина, содержащим сульфоксиминовую группу общей формулы (I) в соответствии с описанием и определением в настоящем документе, а также способам их получения, их применению для лечения и/или профилактики заболеваний, в частности гиперпролиферативных заболеваний, и/или вирусных инфекций, и/или заболеваний сердечно-сосудистой системы. Изобретение также относится к промежуточным соединениям, которые могут применяться для получения указанных соединений общей формулы (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12192852 | 2012-11-15 | ||
PCT/EP2013/073637 WO2014076091A1 (en) | 2012-11-15 | 2013-11-12 | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201590890A1 true EA201590890A1 (ru) | 2015-11-30 |
EA027226B1 EA027226B1 (ru) | 2017-07-31 |
Family
ID=47148672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590890A EA027226B1 (ru) | 2012-11-15 | 2013-11-12 | Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу |
Country Status (43)
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
ES2616441T3 (es) | 2012-10-18 | 2017-06-13 | Bayer Pharma Aktiengesellschaft | Derivados de N-(piridin-2-il))pirimidin-4-amina que contienen un grupo sulfona |
US9670161B2 (en) | 2012-10-18 | 2017-06-06 | Bayer Pharma Aktiengesellschaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
ES2612978T3 (es) | 2012-11-15 | 2017-05-19 | Bayer Pharma Aktiengesellschaft | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
BR112015014178A2 (pt) | 2012-12-17 | 2017-07-11 | Parion Sciences Inc | compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida |
RS55618B1 (sr) | 2012-12-17 | 2017-06-30 | Parion Sciences Inc | Derivati hloropirazin karboksamida korisni za lečenje bolesti kojima pogoduje nedovoljna hidracija sluznica |
WO2015001021A1 (en) * | 2013-07-04 | 2015-01-08 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
JP2017508757A (ja) | 2014-03-13 | 2017-03-30 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含有する5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体 |
US9790189B2 (en) | 2014-04-01 | 2017-10-17 | Bayer Pharma Aktiengesellschaft | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group |
AP2016009483A0 (en) | 2014-04-11 | 2016-10-31 | Bayer Pharma AG | Novel macrocyclic compounds |
EP3207037B1 (en) | 2014-10-16 | 2019-01-23 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group |
US9884849B2 (en) | 2014-10-16 | 2018-02-06 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group |
CN108290903B (zh) | 2015-09-29 | 2021-09-03 | 拜耳医药股份有限公司 | 新的大环磺酰二亚胺化合物 |
JP6888000B2 (ja) | 2015-10-08 | 2021-06-16 | バイエル ファーマ アクチエンゲゼルシャフト | 新規な修飾された大環状化合物 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
PL3601253T3 (pl) | 2017-03-28 | 2022-01-17 | Bayer Aktiengesellschaft | Nowe hamujące ptefb związki makrocykliczne |
CA3057891A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
KR20200119800A (ko) * | 2018-02-13 | 2020-10-20 | 바이엘 악티엔게젤샤프트 | 미만성 거대 b-세포 림프종을 치료하기 위한 5-플루오로-4-(4-플루오로-2-메톡시페닐)-n-[4-[(s-메틸술폰이미도일)메틸]피리딘-2-일]피리딘-2-아민의 용도 |
KR20220113773A (ko) | 2019-12-09 | 2022-08-16 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 사이클린 의존성 키나아제 9 억제제로서의 화합물 및 그의 용도 |
WO2021176045A1 (en) * | 2020-03-06 | 2021-09-10 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
WO2022078309A1 (zh) * | 2020-10-12 | 2022-04-21 | 上海海雁医药科技有限公司 | 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途 |
CN117015539A (zh) * | 2022-03-25 | 2023-11-07 | 成都苑东生物制药股份有限公司 | 一种氨基吡啶类衍生物、其制备方法及用途 |
WO2024044757A1 (en) * | 2022-08-26 | 2024-02-29 | Sanford Burnham Prebys Medical Discovery Institute | Aminopyrimidine and aminotriazine derivatives as myc protein modulators |
WO2024097179A1 (en) * | 2022-11-02 | 2024-05-10 | Vincerx Pharma, Inc. | Combination therapies comprising a cdk9 inhibitor for cancer |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60138645D1 (de) | 2000-12-21 | 2009-06-18 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
CA2589793A1 (en) | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as cdk inhibitors |
DE102006041382A1 (de) * | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
MX2009006536A (es) | 2006-12-22 | 2009-06-26 | Novartis Ag | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. |
EP2094681A1 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
WO2008129080A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
ES2539518T3 (es) | 2007-04-24 | 2015-07-01 | Astrazeneca Ab | Inhibidores de proteínas quinasas |
WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
ES2619585T3 (es) | 2010-03-22 | 2017-06-26 | Lead Discovery Center Gmbh | Derivados de triazina disustituidos farmacéuticamente activos |
WO2012101063A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
US9242937B2 (en) * | 2011-03-02 | 2016-01-26 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted pyridine derivatives |
EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
EP2755948B1 (en) | 2011-09-16 | 2016-05-25 | Bayer Intellectual Property GmbH | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
EP2755956B1 (en) | 2011-09-16 | 2016-05-18 | Bayer Intellectual Property GmbH | 2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors |
US9670161B2 (en) * | 2012-10-18 | 2017-06-06 | Bayer Pharma Aktiengesellschaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
ES2597232T3 (es) | 2012-10-18 | 2017-01-17 | Bayer Pharma Aktiengesellschaft | 4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona |
ES2622583T3 (es) | 2012-11-15 | 2017-07-06 | Bayer Pharma Aktiengesellschaft | 4-(Orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina |
ES2612978T3 (es) | 2012-11-15 | 2017-05-19 | Bayer Pharma Aktiengesellschaft | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina |
WO2015001021A1 (en) | 2013-07-04 | 2015-01-08 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
JP2017508757A (ja) | 2014-03-13 | 2017-03-30 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含有する5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体 |
-
2013
- 2013-11-12 ES ES13792885.9T patent/ES2612978T3/es active Active
- 2013-11-12 UA UAA201505911A patent/UA115254C2/uk unknown
- 2013-11-12 CA CA2891358A patent/CA2891358C/en active Active
- 2013-11-12 SG SG11201503079PA patent/SG11201503079PA/en unknown
- 2013-11-12 ME MEP-2017-16A patent/ME02880B/me unknown
- 2013-11-12 MX MX2015006169A patent/MX2015006169A/es active IP Right Grant
- 2013-11-12 MA MA38090A patent/MA38090B1/fr unknown
- 2013-11-12 LT LTEP13792885.9T patent/LT2928878T/lt unknown
- 2013-11-12 SI SI201330389A patent/SI2928878T1/sl unknown
- 2013-11-12 PL PL13792885T patent/PL2928878T3/pl unknown
- 2013-11-12 AU AU2013346939A patent/AU2013346939B2/en active Active
- 2013-11-12 EA EA201590890A patent/EA027226B1/ru not_active IP Right Cessation
- 2013-11-12 PT PT137928859T patent/PT2928878T/pt unknown
- 2013-11-12 JP JP2015542247A patent/JP6263193B2/ja active Active
- 2013-11-12 AP AP2015008432A patent/AP3872A/en active
- 2013-11-12 WO PCT/EP2013/073637 patent/WO2014076091A1/en active Application Filing
- 2013-11-12 DK DK13792885.9T patent/DK2928878T3/en active
- 2013-11-12 MY MYPI2015701520A patent/MY170609A/en unknown
- 2013-11-12 HU HUE13792885A patent/HUE032868T2/en unknown
- 2013-11-12 US US14/443,279 patent/US9650340B2/en active Active
- 2013-11-12 CN CN201380070440.8A patent/CN105102444B/zh active Active
- 2013-11-12 KR KR1020157015423A patent/KR102242871B1/ko active IP Right Grant
- 2013-11-12 PE PE2015000630A patent/PE20151071A1/es active IP Right Grant
- 2013-11-12 EP EP13792885.9A patent/EP2928878B1/en active Active
- 2013-11-12 RS RS20170009A patent/RS55580B1/sr unknown
- 2013-11-12 BR BR112015010707-9A patent/BR112015010707B1/pt active IP Right Grant
- 2013-11-12 NZ NZ70708413A patent/NZ707084A/en unknown
- 2013-11-13 JO JOP/2013/0330A patent/JO3332B1/ar active
- 2013-11-15 AR ARP130104211A patent/AR093505A1/es active IP Right Grant
- 2013-11-15 TW TW102141761A patent/TWI613193B/zh active
- 2013-11-15 UY UY0001035141A patent/UY35141A/es not_active Application Discontinuation
-
2015
- 2015-04-16 IL IL238322A patent/IL238322A/en active IP Right Grant
- 2015-05-05 PH PH12015501003A patent/PH12015501003B1/en unknown
- 2015-05-14 TN TNP2015000185A patent/TN2015000185A1/fr unknown
- 2015-05-14 CL CL2015001304A patent/CL2015001304A1/es unknown
- 2015-05-15 DO DO2015000118A patent/DOP2015000118A/es unknown
- 2015-05-15 SV SV2015004979A patent/SV2015004979A/es unknown
- 2015-05-15 CR CR20150256A patent/CR20150256A/es unknown
- 2015-05-15 CU CU2015000052A patent/CU20150052A7/es unknown
- 2015-05-15 EC ECIEPI201519323A patent/ECSP15019323A/es unknown
-
2016
- 2016-02-02 HK HK16101158.8A patent/HK1213255A1/zh unknown
- 2016-11-22 HR HRP20161547TT patent/HRP20161547T1/hr unknown
-
2017
- 2017-01-17 CY CY20171100053T patent/CY1118441T1/el unknown
- 2017-04-03 US US15/477,974 patent/US9877954B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590890A1 (ru) | Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу | |
EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
EA201590931A1 (ru) | Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций | |
EA201591527A1 (ru) | Новые производные пиридина | |
UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
EA201591524A1 (ru) | Производные 2-аминопиримидина для лечения вирусных инфекций | |
EA201391495A1 (ru) | Производные пиримидина для лечения вирусных инфекций | |
EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
EA201590892A1 (ru) | Производные n-(пиридин-2-ил)пиримидин-4-амина, содержащие сульфоксиминовую группу | |
EA202090547A2 (ru) | Макроциклические деаза-оксипурины для лечения вирусных инфекций | |
EA201301320A1 (ru) | 4-арил-n-фенил-1,3,5-триазин-2-амины, которые содержат сульфоксиминную группу | |
EA201591166A1 (ru) | Ингибиторы аутотаксина | |
EA201890333A1 (ru) | Противовирусные соединения | |
EA201492002A1 (ru) | Противовирусные соединения | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
EA201690520A1 (ru) | Способ получения замещенных 5-фтор-1h-пиразолопиридинов | |
WO2014060375A3 (en) | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group | |
EA201591451A1 (ru) | Модуляторы flap | |
WO2014060493A3 (en) | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group | |
EA201600288A1 (ru) | Замещенные фенилаланиновые производные | |
EA201592242A1 (ru) | Производные пиридона для лечения вирусных инфекций и других заболеваний | |
EA201501177A1 (ru) | Фармацевтические композиции | |
EA201590363A1 (ru) | Новые производные пиридина | |
EA201101703A1 (ru) | 17β-АЛКИЛ-17α-ОКСИЭСТРАТРИЕНЫ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ KG TJ TM |